reports
Australian Clinical Labs Limited: 1 director
A director at Australian Clinical Labs Limited maiden bought 20,000 shares at 2.358AUD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
- Hugo Solvet
ALCON: Consensus above FY19 guidance on profitability | NEUTRAL | CHF5...
ALCON - NEUTRAL | CHF57(-7%) Consensus above FY19 guidance on profitability In-line Q1 sales (up 4%cc) Profitability low on one-time items FY19 guidance leaves limited room of manoeuver Profit-taking risk on the share price at opening
- Hugo Solvet
- Eric Le Berrigaud
- Gary Waanders
- Hugo Solvet
- Jean-Jacques Le Fur
- Ross Blair
- Victor Floc’h
- Hugo Solvet
ALCON | Better standing on its two own feet | Not rated | FVCHF57
Since its acquisition by Novartis in 2010, Alcon has had a chequered history. Following the implementation of a turnaround plan in 2016, which is now entering its last phase, Alcon’s foundations have been fixed and the division is back on track. Alcon is set to deliver above-market growth (BGe 4.9%CER), building on its leading market shares of 43% and 21% in the surgical and vision care businesses respectively. Leveraging its infrastructure should enable Alcon to ramp up its Core EBIT margin f...
- Alexander Korda
Buying Opportunity Post Spin With Novartis’ Eye Care Business
The Spinoff of the world’s largest eye-care business, Alcon, Inc. (ALC), is just one of four major strategic transactions Novartis AG (NOVN) has made over the last year, with CEO Narasimhan ramping up the focus on its core leading medicines. New numbers prompted our update to the analysis however, we believe there can be a better entry point into this situation post-Spin. What's Interesting? The Edge Intelligence... After having a connection for more than 10-years, Novartis AG (NOVN), the Swi...
- Alexander Korda
Major Restructuring at Swiss Pharma Giant Creates World's Largest Eye-...
The upcoming annual general meeting (Feb 28th) will likely give further clarity for the upcoming Spinoff of the world’s largest eye-care business, Alcon, Inc. (ALC). This Spinoff will be the 4th major strategic transaction over the last year for Novartis (NOVN) as CEO Narasimhan ramps up the focus as a leading medicines company. What's Interesting? The Edge Intelligence... Novartis AG (NYSE: NVS; SIX: NOVN), the Swiss pharmaceutical giant, will be spinning off its previously acquired (after s...
A director sold 48,550,000 shares at 0.016AUD and
A director at Alchemia Limited sold 48,550,000 shares at 0.016AUD and the significance rating of the trade was 86/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.